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Abstract
Recently, several authors have reported that optimal primary cytoreduction of both hepatic and extrahepatic disease is not
only feasible but improves survival. However, the role of hepatic resection in combination with secondary cytoreduction for
epithelial ovarian cancer is unclear. Patients with recurrent ovarian cancer and metachronous intrahepatic metastases are
often evaluated by a multidisciplinary team at the Mayo Clinic comprising pelvic and hepatobiliary surgeons for
consideration of cytoreductive surgery. The purpose of this report is to update the outcome of cytoreductive surgery
including hepatic resection for patients with metastatic ovarian carcinoma.
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Introduction
Currently, the standard treatment for newly diag-
nosed advanced stage ovarian cancer includes defini-
tive staging, aggressive cytoreductive surgery, and
chemotherapy [1,2]. However, /70% of patients
with advanced stage disease experience recurrence.
The benefits of secondary cytoreductive surgery for
recurrent ovarian cancer depend on tumor character-
istics, feasibility of optimal secondary cytoreduction,
and chemosensitivity. Complete secondary cytoreduc-
tive surgery in some patients has been reported to
be technically feasible and has had acceptable perio-
perative morbidity and mortality. Patients who
undergo this approach have shown improved survival
in retrospective studies compared with patients in
whom this treatment was not possible [3/9].
Multiple studies have shown a consistent survival
benefit when primary cytoreductive surgery precedes
the initiation of cytotoxic therapy for advanced
ovarian cancer [10/12]. Although there is less en-
thusiasm for aggressive cytoreduction in patients with
stage IV disease due to hepatic metastases, there is no
convincing evidence to suggest that cytoreduction
with hepatic involvement is less efficacious clinically
than for stage IIIC disease in patients with a similar
tumor residuum. Recently, several authors have
reported that optimal primary cytoreduction of both
hepatic and extrahepatic disease is not only feasible
but improves survival. In fact, there is significant
survival benefit when surgical cytoreduction, includ-
ing hepatic resection, is incorporated in the primary
treatment algorithm of patients with stage IV disease
[2,13/16].
The benefits of cytoreductive surgery are also
evident in patients with recurrent disease, particularly
those who have prolonged disease-free intervals and
readily defined site(s) of tumor involvement. Optimal
surgical outcomes are easily achieved in patients with
an apparent solitary recurrence and a survival benefit
has also been shown after completion of secondary
cytoreduction in patients with more extensive disease,
particularly in conjunction with multiple courses of
salvage chemotherapy [3,5,6,17]. However, the role
of hepatic resection in combination with secondary
cytoreduction for epithelial ovarian cancer is unclear.
Not infrequently, patients with recurrent ovarian
cancer and metachronous intrahepatic metastases
are evaluated by a multidisciplinary team at the
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Mayo Clinic comprising pelvic and hepatobiliary
surgeons for consideration of cytoreductive surgery.
The purpose of this report is to update the outcome of
cytoreductive surgery including hepatic resection for
patients with metastatic ovarian carcinoma.
Patients and methods
We updated our previously published experience [9],
and identified 35 patients who have had minor (less
than three segments) or major (more than three
segments) hepatic resection. Data were extracted
from clinic records as per the prior report. The
literature was reviewed for reports addressing hepatic
resection for gynecological malignancies specifically
or for noncolorectal, nonneuroendocrine (NCNNE)
metastases. Survival herein was estimated according
to the method of Kaplan and Meier [18]. The log-
rank test was used to assess univariate comparison of
the survivorship curves [19]. Outcomes for the
disease-specific survival were simply tabulated as
reported for recurrent ovarian carcinoma from 1976
to 2003 at Mayo Clinic, Rochester.
Results
The overall median disease-specific survival was
27.4 months after hepatic resection. When cytoreduc-
tion was complete, without macroscopic residual
disease, 25 patients demonstrated a median survival
of 41.3 months. When gross tumor was present
after surgery (10 patients) the median disease-
specific survival was 11.7 months (log-rank pB/
0.05) (Figure 1). If optimal cytoreduction is defined
as extrahepatic or hepatic residual disease 5/1 cm
in greatest diameter, the median disease-specific
survival after surgery for the 29 patients with optimal
secondary cytoreduction was significantly greater than
for the 6 patients in whom optimal cytoreduction was
not possible (41.3 vs 5.7 months, log-rank pB/
0.0001) (Figure 2). No perioperative deaths occurred,
and only one patient required reoperation due to a
small bowel perforation.
Residual tumor of 5/1 cm in greatest diameter was
the most significant factor associated with improved
disease-specific survival. Also, patients whose pre-
vious operation for ovarian cancer was performed at
least 1 year before the hepatic resection had improved
disease-specific survival compared with those whose
previous surgery was 5/1 year before the hepatic
resection (31.7 vs 15.1 months, p/0.01). The
majority of our patients underwent other procedures
to achieve optimal tumor reduction at the time of
hepatic resection, with 12 of the 35 (34.3%) patients
having bowel resection; and 28 (80%) undergoing
other additional procedures apart from the liver
resection. Based on our retrospective data, the num-
ber of liver lesions, their distribution (unilobular or
multilobar) and tumor grade were not associated with
survival [9]. Outcomes from the literature are shown
in Table I. Although definitive conclusions from these
heterogeneous, small studies is difficult, the median
survival of the patients undergoing hepatic resection
for metastatic ovarian cancer have varied from 27 to
60 months depending on the surgical selection
criteria.
Discussion
Five-year disease-specific survival after hepatic resec-
tion in patients with hepatic metastases from NCNNE
carcinoma is comparable to the 5-year survival of
patients after hepatic resection for colon cancer,
ranging from 9% to 38%, depending on the origin
of the primary tumor [18/20]. The greatest survival
benefit has been achieved in tumors of genitourinary
origin [18/20]. However, most studies on hepatic
resection for NCNNE metastases are small and the
outcome is based on the collective population and not
specific pathology. To optimally estimate the value of
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Figure 1. The 5-year disease-specific survival of patients with no
macroscopic residual disease after secondary cytoreductive surgery,
including hepatic resection, versus those with macroscopic residual
disease after secondary cytoreductive surgery.
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Figure 2. The 5-year disease-specific survival of patients with
residual disease equal orB/1 cm after secondary cytoreductive
surgery, including hepatic resection, versus those with residual
disease/1 cm after secondary cytoreductive surgery.
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hepatic resection, studies focused on a single tumor
type are needed.
Our report supports the conclusion that secondary
tumor cytoreductive surgery in ovarian cancer, in-
cluding hepatic resection, can be performed safely by
an experienced combined surgical team as suggested
by others [3/6,8,9,18,20]. If cytoreduction in these
patients is optimal, they appear to have the same
survival advantage as patients with a similar volume of
residual disease but without a history of hepatic
metastases. We concur with others that only a select
group of patients who present with recurrent disease
limited to resectable sites in the liver can benefit
from hepatic resection [21]. Moreover, we believe
that hepatic resection can be achieved with little
additional morbidity at the time of secondary surgical
cytoreduction. The two most important factors affect-
ing the recommendation for surgical resection are the
ability to achieve overall optimal cytoreduction and
the length of the disease-free interval preceding
operation (/1 year from previous surgery). Optimal
cytoreduction is the most important factor in the
decision to incorporate hepatic resection in the
treatment plan for patients with metachronous liver
metastases. Indeed, if optimal hepatic cytoreduction
is possible anatomically, there is no evidence to
suggest that hepatic resection should not be done in
patients who have other intra-abdominal sites of
recurrence and are undergoing secondary cytoreduc-
tive surgery.
The independent impact of hepatic resection for
metastatic ovarian carcinoma beyond chemotherapy
cannot be directly calculated without a randomized
trial. The infrequency of this clinical situation and the
heterogeneity of such patients regarding tumor and
other treatment factors will likely preclude such a
study. However, comparable evidence in patients with
primary ovarian cancer and metastatic colorectal
cancer strongly suggests benefit for hepatic resection
of hepatic metastases. In conclusion, hepatic metas-
tases should not preclude attempts at optimal sec-
ondary cytoreductive surgery. When cytoreductive
resection is performed jointly by pelvic and hepato-
biliary surgeons, morbidity and mortality appear no
different from that historically attributed to aggressive
surgical debulking itself.
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